SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about its ELEVIDYS therapy and revenue outlook [1][4]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Sarepta made false and misleading statements regarding the safety and approval potential of its ELEVIDYS therapy [4]. - Investors who purchased Sarepta's securities between June 22, 2023, and June 24, 2025, are encouraged to participate in the class action before the deadline of August 25, 2025 [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Impact on Investors - The misleading statements led investors to believe in a strong growth potential for the ELEVIDYS therapy, which ultimately resulted in financial damages when the truth was revealed [4]. - The Schall Law Firm specializes in securities class action lawsuits and aims to represent investors seeking to recover losses incurred due to the alleged misconduct [5].